Compare VIV & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIV | MEDP |
|---|---|---|
| Founded | 1973 | 1992 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 18.3B |
| IPO Year | 1998 | 2016 |
| Metric | VIV | MEDP |
|---|---|---|
| Price | $11.77 | $619.10 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 8 | 14 |
| Target Price | $13.56 | ★ $651.31 |
| AVG Volume (30 Days) | ★ 1.6M | 216.6K |
| Earning Date | 11-10-2026 | 10-21-2026 |
| Dividend Yield | ★ 6.75% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | N/A | ★ 13.37 |
| Revenue | N/A | N/A |
| Revenue This Year | $7.05 | $12.62 |
| Revenue Next Year | $5.56 | $6.03 |
| P/E Ratio | ★ $22.12 | $47.36 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.70 | $373.00 |
| 52 Week High | $17.26 | $693.97 |
| Indicator | VIV | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | 40.33 |
| Support Level | $11.05 | $570.70 |
| Resistance Level | $12.14 | $636.66 |
| Average True Range (ATR) | 0.29 | 19.13 |
| MACD | 0.04 | -5.66 |
| Stochastic Oscillator | 52.96 | 7.14 |
Telefonica Brasil, known as Vivo, is the largest wireless carrier in Brazil with 103 million customers, which is equal to about 38% market share. The firm is strongest in the postpaid business, where it has 72 million customers, or about 40% share of this market. Wireless services and equipment contribute about 70% of total revenue. Vivo is the incumbent fixed-line telephone operator in Sao Paulo state and also owns an extensive fiber network across the country. The firm provides internet access to 8 million households on this network. The firm also sells pay-TV and phone services to its fixed-line customers. Finally, corporate data and IT services, including cloud computing support, contribute about 10% of total revenue.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.